Life Sciences Archive » October, 2011

Life Sciences - October, 2011

174 articles

• Calif. Court Tosses Pay-For-Delay Suit Over Bayer's Cipro
• Amylin Can't Block Lilly's Rival Drug Sales: 9th Circ.
• Cephalon Patent Found Invalid In Pay-For-Delay Case
• Insured Can't Appeal Cancer Coverage Ruling: Judge
• AstraZeneca, Pozen Want Generic Arthritis Drug Blocked
• Medical Device Preemption Case Rejected By High Court
• Obama Orders FDA Crackdown On Drug Shortages, Gouging
• Fed. Circ. Won't Rethink BD Syringe Patent Fight
• Divisive Teva-Merck IP Ruling Stays Out Of Supreme Court
• High Court Vacates Generics Preemption Ruling
• Momenta Gets Rivals' Sale Of Generic Lovenox Barred
• Pfizer Failed To Warn Of Zoloft Birth Defect Risks: Suits
• Ex-Ky. Judge Disbarred Over $126M Fen-Phen Fees
• Sun Capital's $36.6M Bid For Body Armor Co.'s Assets OK'd
• Pharmacies Bring Pfizer-Wyeth Merger Suit To High Court
• Coventry Nears Copay Case Deal On Eve Of Trial
• County Can't Pursue Own Avandia False Ad Claims: Judge
• HealthSpring Investor Tries To Halt Cigna Purchase
• Patterns In Post-Adjudication Of Infringement Damages
• Bristol-Myers Can't Shake Suit Over Kickbacks Scheme
• Yaz MDL Plaintiffs Say FDA Should See Confidential Docs
• Yaz, Other Birth Control Drugs Boost Blood Clot Risk: FDA
• BioMed Secures Tenant For I-270 Office
• Jury Awards Novozymes $18M In IP Fight With DuPont Unit
• Mass. REIT Breaks Ground On $500M Alexandria Center
• Case Study: Merck V. Garza
• McKesson Pays $82M To End Drug Price Inflation Suit
• Astellas Drug Reps Get Initial Class Cert. In OT Case
• Bristol-Myers Faces Italian Scrutiny Over '90s Ops
• Barclays PE Snaps Up Swiss-Owned Chemical Co.
• Medtronic Catheter Side Effects Are Cause For Concern: US
• Investor Sues Google Directors Over Online Drug Sales
• China's Global Pharm Scores $15M To Fund Future Buys
• You Cannot Sue For What They Cannot Do
• Contractor For 9/11 Lighting Tribute Seeks Ch. 11
• Merchant & Gould Adds Sutherland IP Pro To Atlanta Office
• Danisco Fails To Prove Novozymes Ethanol IP Invalid
• Olympus Head Steps Down Amid Merger Fee Scandal
• Stikeman Guides Cardinal Health's $162M Futuremed Buy
• GSK Hid Morning Sickness Drug's Birth Defect Risks: Suit
• 8th Circ. Won't Revive Minn. Prempro Suits
• Eli Lilly Settles Suit Over Generic Prozac Suicide Risk
• Omnicare Faces Fresh Suit Over Alleged Medicare Fraud
• Novartis Unit Subpoenaed In HHS Fraud Investigation
• Ex-Orrick Atty To Launch Marten Law Office In SF
• Olympus Struggles To Survive Merger Fee Scandal
• Body Armor Co. Settles Defective Vest Claims For $1M
• The Curious Case Of Urology Of Central Pa.
• Eli Lilly Pulls 'Ineffective' Sepsis Drug Xigris
• Penn Medicine, REIT Invest $72M In Hospital High-Rise
• Drug Cos. Made Record Pay-For-Delay Deals In 2011: FTC
• Accel-KKR Invests In Scientist Networking Co. Expansion
• Amgen To Pay $780M To Settle Drug Sales Suits
• FDA Raises Doubts Over Insufficient AtriCure Trial
• Software Co. Investors Can't Revive Suit Over Oracle Buy
• Bristol-Myers, Novartis Settle With Teva Over HIV Drug IP
• Biotronik Can't Seek $100M From J&J Over Stents: Judge
• Chantix No Riskier Than Nicotine Patch, Gum: Studies
• Olympus Faces FBI Probe Over $687M Merger Advisory Fee
• HIPAA — Paper Law No More
• 9th Circ. Backs Insurer's Win In Ventana IP Defense Row
• South Korea Fines GSK $2.6M Over Pay-For-Delay Deal
• Alkermes, Jazz Aim To Block Torrent's Generic Luvox
• Cigna Buys HealthSpring For $3.8B With Davis Polk Help
• Wyeth Shareholders Seek Class Cert. In Pristiq Suit
• Actavis, Mylan Can Use Expert's Word In Heart Drug MDL
• MillerCoors, Nestle, Insurers Sued Over Navy Tech IP
• DLA Piper Life Sciences Partner Jumps To Fenwick
• Winston & Strawn Helps AAR Land Teleflex Units For $280M
• AMAG Shareholders Reject $268M Allos Merger
• Pros And Cons Of A CMS-FDA Parallel Review Program
• EU Scrutinizes J&J, Novartis Generic Painkiller Deals
• Systemic Discrimination? Let The Statistics Talk
• Pfizer Unit Off The Hook In Prempro Breast Cancer Case
• Abbott, Fournier Settle With Impax Over Generic Trilipix
• Fla. Appeals Court Nixes Ex-Hospital Chief's $10M Libel Win
• Pfizer Pays $14.5M To End Whistleblowers' FCA Suit
• Investor Says K-V Lied About Pregnancy Drug's Prospects
• Wyeth Sued Again Over Effexor Generics Delays
• Case Study: FTC V. Lundbeck
• Novartis Stuck With Sanctions In Bone Drug MDL
• Concrete Buyers Want $18M In Antitrust Deals OK'd
• FDA Deems CareFusion Ventilator Defect High-Risk
• Novo Ramps Up Prandin IP Battle With Sandoz Suit
• Miller & Chevalier Adds Ex-Baxter Atty
• Abbott Labs Splits In Bid To Drive Growth
• Warner Chilcott Hits Watson With Atelvia Patent Suit
• Judge Tosses Elan Shareholder Suit Over $1B J&J Deal
• EU High Court Bans Patents For Embryonic Stem Cells
• Abbott, Lilly Fight Sales Reps' OT Claims In 7th Circ.
• FDA Warns GSK Over Manufacturing Violations In UK
• FDA Chemist Pleads Guilty To $4M Insider Trading Plot
• Fed. Circ. Nixes Apotex $108M Interest Payout Over Plavix
• Floundering Graceway Wins OK For Asset Auction
• Pfizer Wins Attys' Fees From Teva In Viagra Patent Row
• Severance In Multiplaintiff Pharmaceutical Cases
• Conceptus Scores $18.8M Victory In Hologic Patent Fight
• Ex-Alfacell Exec's Securities Suit Gets The Boot
• Alcon Sues Generics Maker Over Nasal Spray Patent
• Ametek Acquires Privately Held Eye Care Co. For $150M
• Bausch & Lomb, Insurer Settle Infection Coverage Row
• Davis Polk Advises Roche In $230M Deal To Buy Anadys
• GSK Settles Direct Buyers' Wellbutrin Claims For $49M
• Innovative Corporate Counsel: Elpidio 'PD' Villarreal
• J&J Unit Bests Suit Over Levaquin Injuries
• Teva, Cephalon Win EU Antitrust OK For $6.8B Tie-Up
• SEC's Headache Over Conflict Mineral Rules Won't Go Away
• Pharma Co. Wants Ropes & Gray Atty Tossed From IP Suit
• Sens. Target FDA Regs To Speed Medical Device Review
• Amgen Asks 9th Circ. To Undo Shareholder Class Cert.
• Trust Can't Boot Abbott's Humira Patent Challenge
• PPD Investor Sues Over $4B Carlyle, Hellman Buyout
• Noven Tries To Block Watson's Generic Daytrana
• Allos Settles Investor Suit Over $686M AMAG Tie-Up
• AstraZeneca, Sun Pharma Settle Over Nexium Generic
• Centurion Shores Up Biotech Outfit With $10M Investment
• Siemens, U. Of Neb. Settle Lab Test Patent Suit
• Innovative Corporate Counsel: Amy Schulman
• Judge Pares Solvay Drug Marketing Scheme Suit
• Antitrust Group Urges 8th Circ. To Rehear FTC Drug Suit
• Case Study: PharmAthene V. SIGA
• Innovative Corporate Counsel: Marla Persky
• Bayer, Merial Hit With $32B Class Suit Over Flea Meds
• Allergan Sues Hi-Tech Over Pinkeye Drug Patents
• Teva, Baxter Told To Pay $104M In Propofol Hepatitis Case
• Pfizer, Actavis End Patent Fight Over Generic Lipitor
• Google, TPG, Others Invest $15M In DNA Data Firm
• SciClone Shells Out $2.5M To Investors Amid FCPA Probes
• Purdue Sues Ranbaxy Again Over Generic OxyContin
• Applied Scores Victory In Covidien Surgical Tool IP Fight
• FDA Tweaks Cancer Drug Warnings Over Hypertension Risk
• Amylin Calls For Lilly Marketing Injunction In 9th Circ.
• Seattle Genetics Insider's Brother Gets 18 Months
• Investor Says Stereotaxis Hid Problems With Products
• FCPA Lawsuits — Not Just For The Government
• Drugmaker Takes FDA Generics Rule Fight To DC Circ.
• Teva Must Surrender Generics To Get Cephalon: FTC
• Momenta Stops Rivals' Generic Lovenox Launch For Now
• Gores' $30M Bid Leads Point Blank Ch. 11 Sale
• Simpson, Kirkland Aid Investors In $1.6B KCI Notes Deal
• Fulbright Securities Atty Jumps To Greenberg
• HHS Urges DC Circ. To Keep Ban On OxyContin Misbranders
• Baxter To Exit Drug Price Inflation MDL For $30M
• FTC Speeds Approval Process For Divestiture Order Tweaks
• The Downside Of Tort Reform
• Corporate Counsel Beware: Limits Of 'No Contact Rule'
• Pfizer Sues Watson Over Embeda Generic
• A Creative Fix To A Medical Monopoly Problem
• SEC Sues Ex-Hansen Execs Over Fake Catheter Sales
• Krill Oil Extractor Neptune Sues Rivals Over New Patent
• Innovative Corporate Counsel: Moze Cowper
• Creabilis Raises $20M To Develop Dermatology Drugs
• AstraZeneca, Accord Settle Seroquel XR Patent Spat
• Web Pharmacies Sold Generics Under Celgene Marks: Suit
• Generics Cos. Rip AstraZeneca's Crestor IP In Fed. Circ.
• Ricky Nelson's Estate Sues Capitol Over Royalties
• Questioning US Antitrust Liability Of Foreign Defendants
• Relpax Patent Fight Revived After Stalled Settlement
• Impax Suit Against Pfizer Denied In IP Fight Over Detrol
• Jury Awards Man $48M For Extreme Reaction To Motrin
• Elan Again Beats Claims It Hid Drug Trial Data
• Pfizer Sued By Drugmaker Over Yanked Feed Additive
• Mispackaged Birth Control Pills Caused Pregnancy: Suit
• Genzyme Gets Rival Pain Med Barred For Now In IP Row
• Watchdog Releases Contractor Misconduct Database
• FDA Pitches New Transparency, Social Media Plans
• Tucker Ellis Grabs 2 Jones Day Litigators In Cleveland
• 7th Circ. Overturns Affymax Foreign Patent Ruling
• Bringing ANDA Litigation To East Texas
• Shareholder Suit Over J&J Recall, Kickback Woes Tossed
• Jury Lets Merck Off Hook In Fosamax Bellwether Suit
• Mylan Can't Get Top Court Review Of $76M Antitrust Ruling
• Carlyle, Hellman To Take PPD Private For $3.9B
• Proskauer Says J&J Heir's Malpractice Suit Time-Barred